20 Spinal Muscular Atrophy Clinical Trials in Fairfax, VA (2026)

Q: How do I join a clinical trial in Fairfax?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you.

Recruiting Spinal Muscular Atrophy Studies in Fairfax

NCT07349537Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or...

Fairfax, VAPHASE1574 participantsRevolution Medicines, Inc.

View Study Details

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Fairfax, VAPHASE1400 participantsBayer

View Study Details

NCT06043817Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Study STX-721-101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721 in participants with non-small cel...

Fairfax, VAPHASE1345 participantsAntares Therapeutics, Inc

View Study Details

NCT05142189Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in c...

Fairfax, VAPHASE1320 participantsBioNTech SE

View Study Details

NCT07538804Recruiting

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetic...

Fairfax, VAPHASE1294 participantsAvistone Biotechnology Co., Ltd.

View Study Details

NCT07098338Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several ...

Fairfax, VAPHASE2278 participantsAstraZeneca

View Study Details

NCT07174583Recruiting

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC....

Fairfax, VAPHASE1262 participantsIDEAYA Biosciences

View Study Details

NCT07519655Recruiting

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it be...

Fairfax, VAPHASE1250 participantsPfizer

View Study Details

NCT06515990Recruiting

A Study of DM005 in Patients With Advanced Solid Tumors

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by...

Fairfax, VAPHASE1208 participantsDoma Biopharmaceutical（Suzhou）Co., Ltd.

View Study Details

NCT06616766Recruiting

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberrat...

Fairfax, VAPHASE1201 participantsYuhan Corporation

View Study Details

NCT07221474Recruiting

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intism...

Fairfax, VAPHASE2180 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07085091Recruiting

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors...

Fairfax, VAPHASE1170 participantsALX Oncology Inc.

View Study Details

NCT07531095Recruiting

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination d...

Fairfax, VAPHASE1160 participantsAmgen

View Study Details

NCT07458347Recruiting

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutatio...

Fairfax, VAPHASE1145 participantsKestrel Therapeutics, Inc.

View Study Details

NCT06905197Recruiting

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations....

Fairfax, VAPHASE1140 participantsDizal Pharmaceuticals

View Study Details

NCT07407933Recruiting

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untre...

Fairfax, VAPHASE1118 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT06332755Recruiting

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and ...

Fairfax, VAPHASE176 participantsLG Chem

View Study Details

NCT07227025Recruiting

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \[RP2CD\]) of amivantamab and olomorasib combination therapy and to assess how well the combi...

Fairfax, VAPHASE160 participantsJanssen Research & Development, LLC

View Study Details

NCT07140016Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some ...

Fairfax, VAPHASE140 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT07315113Recruiting

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)...

Fairfax, VAPHASE118 participantsNuvectis Pharma, Inc.

View Study Details

About Spinal Muscular Atrophy Clinical Trials in Fairfax

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.

There are currently 20 spinal muscular atrophy clinical trials recruiting participants in Fairfax, VA. These studies are seeking a combined 4,239 participants. Research is being sponsored by Revolution Medicines, Inc., Bayer, Antares Therapeutics, Inc and 17 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Spinal Muscular Atrophy Clinical Trials in Fairfax — FAQ

Are there spinal muscular atrophy clinical trials in Fairfax?

Yes, there are 20 spinal muscular atrophy clinical trials currently recruiting in Fairfax, VA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fairfax?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fairfax research site will contact you about next steps.

Are clinical trials in Fairfax free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fairfax studies also compensate for your time and travel.

What spinal muscular atrophy treatments are being tested?

The 20 active trials in Fairfax are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.

Data updated September 2, 2026 from ClinicalTrials.gov